(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Worldwide Objections Ideal For A Golf Outing - 2Manual for Wonderful Getaway destination
- 3Minneapolis ICE shooting: Woman dies after federal agent opens fire on her vehicle amid immigration crackdown
- 4Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- 5King Charles shares cancer treatment update, says it's a 'personal blessing'
- Germany paves the way for tighter EU asylum rules
- I’m a doctor. Here are 10 science-backed tips to help you get healthier.
- Eco-Accommodating Kitchen Machines: 4 Picks for a Manageable Home
- Ukrainian foreign minister appeals for funds for drones
- Make your choice for the sweet that transports you to its nation of beginning!
- FDA updates risk classification for voluntary shredded cheese recall
- A milestone for Artemis II: Astronauts enter the 'lunar sphere of influence'
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- Big majority in Germany call Berlin's efforts on gas prices too weak
